Novus Therapeutics NVUS shares are trading lower on Tuesday.
Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.
Novus Therapeutics Inc is engaged in the biotechnology sector. As a pharmaceutical company, it is focused on the acquisition, development, and commercialization of ear, nose, and throat related products.
Novus shares were trading 11.79% lower at 54 cents at the time of publication on Tuesday. The stock has a 52-week high of $1.82 and a 52-week low of 25 cents.
Related Links:
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
